Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting.

Living with psoriasis presents unique challenges, but with the right skincare routine, you can maintain healthy skin.

Icotrokinra had more significant improvements than placebo for multiple skin clearance measures following 16 weeks of treatment for plaque psoriasis in adolescents and adults. Icotrokinra is ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin. Johnson & Johnson has shared positive data from a subgroup analysis of ...

A video made rounds on social media showing Meena purportedly grabbing BJP mandal president Hanuman Dixit by the collar while he was sitting in a car.

Learn how Vitamin C can help remove bad cholesterol from your arteries and prevent plaque buildup. We also cover the benefits of Vitamins B3 and B5. Don't miss these essential tips for maintaining ...

Deucravacitinib use for 4 years among patients with plaque ... 4 years. Scalp and fingernail PGA 0/1 responses were also durable, with rates of 70.8% and 57.9%, respectively. Patient-reported outcomes ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in treating moderate-to-severe plaque psoriasis (PsO). The data revealed ...

The trial aims to assess the therapy’s safety and efficacy in treating moderate-to-severe plaque psoriasis. Credit: Fuss Sergey/Shutterstock. Johnson & Johnson (J&J) has reported data from the Phase ...

Accessed April 2025. 6 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study. The randomized ...